The Trump administration has reached a landmark agreement with Eli Lilly and Novo Nordisk to reduce prices for their popular weight-loss medications. In exchange, the pharmaceutical giants will receive tariff relief and expanded Medicare access. President Trump announced the deal from the Oval Office, highlighting his administration’s efforts to lower healthcare costs.
about Trump Cuts Drug Prices for Lilly, Novo in Tariff Deal
FinanceNews Article 
November 7, 2025 | 00:00
November 7, 2025 | 00:00
FinanceNews Article November 6, 2025 | 23:59
November 6, 2025 | 23:59
FinanceNews Article November 6, 2025 | 20:16
November 6, 2025 | 20:16
FinanceMarket Report November 2, 2025 | 17:23
November 2, 2025 | 17:23
Eli Lilly
Trump Cuts GLP-1 Drug Prices, Expands Medicare Coverage
The Trump administration has secured a groundbreaking agreement with pharmaceutical giants Eli Lilly and Novo Nordisk that will dramatically reduce prices for GLP-1 medications while expanding Medicare coverage for obesity treatment for the first time. The deal, announced Thursday, brings some monthly drug costs down to approximately $250 and establishes price caps for future medications, marking a significant shift in healthcare policy that could pressure insurers to revisit restrictive coverage rules that have limited patient access to these transformative treatments.
about Trump Cuts GLP-1 Drug Prices, Expands Medicare CoverageLilly, Novo Cut Drug Prices for Medicare in Trump Deal
In a landmark pharmaceutical pricing agreement, Eli Lilly & Co. and Novo Nordisk A/S have secured deals with the Trump administration to significantly reduce prices for their blockbuster weight-loss drugs. The arrangement, announced Thursday at a White House event with President Donald Trump, provides the pharmaceutical giants with tariff relief in exchange for making these highly sought-after medications available to certain Medicare patients, representing a major shift in drug pricing policy and access for older Americans.
about Lilly, Novo Cut Drug Prices for Medicare in Trump DealPharma Investment Surge: Policy Clarity & Innovation Drive Growth
Pharmaceutical companies are experiencing renewed investor interest driven by strong drug pipelines and reduced regulatory risks. The sector benefits from aging global populations and clearer U.S. drug pricing policies that enhance long-term outlook. Leading innovators like Eli Lilly and Merck are at the forefront of this resurgence, with targeted investment vehicles like the PPH ETF providing access to these top performers.
about Pharma Investment Surge: Policy Clarity & Innovation Drive GrowthTrump’s Ozempic Price Comments Hit Novo Nordisk, Lilly Shares
Pharmaceutical giants Novo Nordisk and Eli Lilly faced immediate market pressure after former President Donald Trump declared that the price of diabetes drug Ozempic could plummet to just $150 monthly—a dramatic reduction from its current $1,000 list price. Trump’s Oval Office comments specifically targeted what he called ‘the fat loss drug’ and suggested similar pricing for Lilly’s competing treatments Mounjaro and Zepbound, threatening the dominant position of both companies in a market projected to exceed $95 billion by 2030.
about Trump's Ozempic Price Comments Hit Novo Nordisk, Lilly SharesMarket Jitters: Bank Stocks Fall, Credit Fears Deepen
US financial markets face renewed pressure as bank stocks tumble amid deepening credit concerns, with Zions Bancorp and Western Alliance leading a sector-wide selloff following fraud allegations. Simultaneously, pharmaceutical giants Novo Nordisk and Eli Lilly decline after former President Trump’s comments about potential Ozempic price reductions, while the auto industry anticipates tariff relief on imported parts. The market turbulence reflects broader anxieties as Treasuries extend their rally and the dollar heads for its largest weekly drop since July.
about Market Jitters: Bank Stocks Fall, Credit Fears DeepenSPY ETF: 89.72% Gain in 5 Years Shows S&P 500 Power
The SPDR S&P 500 ETF (SPY) has delivered an impressive 89.72% total return over the past five years, transforming a $10,000 investment into $18,972. This remarkable performance underscores the enduring power of broad-market, low-cost investing through exchange-traded funds, demonstrating why SPY remains a cornerstone for investors seeking diversified exposure to America’s top companies without the complexities of stock-picking or market-timing.
about SPY ETF: 89.72% Gain in 5 Years Shows S&P 500 Power5 Vanguard ETFs for Retirement Income & Growth
Amid market uncertainty and economic headwinds, Vanguard ETFs offer investors a compelling combination of safety, diversification, and attractive yields. These five carefully selected funds provide exposure to real estate, dividend growth, and mega-cap stocks while maintaining low expense ratios. Each ETF has demonstrated strong recovery since April lows while delivering consistent dividend payments, making them ideal for retirement portfolios seeking both income and growth potential.
about 5 Vanguard ETFs for Retirement Income & GrowthPfizer Dodges Trump Tariffs With 85% Drug Price Cuts
In a strategic maneuver that reshapes pharmaceutical pricing dynamics, Pfizer has secured a three-year exemption from President Donald Trump’s threatened tariffs by committing to slash some drug prices by up to 85% and establishing direct sales channels to American consumers. This landmark agreement represents the latest example of Trump’s transactional approach to trade policy, using tariff threats as leverage to achieve domestic policy objectives while providing temporary relief to major corporations facing potential import duties.
about Pfizer Dodges Trump Tariffs With 85% Drug Price CutsPfizer Avoids Tariffs, Cuts Drug Prices in Trump Deal
In a landmark move that sent shockwaves through global pharmaceutical markets, Pfizer has secured a crucial agreement with the Trump administration to avoid tariffs by committing to lower drug prices for American consumers. The deal, which includes a massive $70 billion domestic investment pledge, represents a significant victory for the pharmaceutical giant and sets a new precedent for industry pricing strategies. With competitors Eli Lilly and Merck expected to follow suit, this development signals a fundamental shift in how pharmaceutical companies navigate trade policy while addressing public pressure over medication costs.
about Pfizer Avoids Tariffs, Cuts Drug Prices in Trump Deal